Overview

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Status:
Completed
Trial end date:
2010-02-01
Target enrollment:
Participant gender:
Summary
Study of Yttrium-ibritumomab (Zevalin) For the treatment of Patients with Relapsed & Refractory Mantle Cell Lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
Biogen
Treatments:
Antibodies, Monoclonal
Rituximab